Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : SYN-020
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Recipient : Theriva Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
September 16, 2021
Lead Product(s) : SYN-020
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Recipient : Theriva Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : SYN-020
Therapeutic Area : Gastroenterology
Study Phase : Phase I
Recipient : Theriva Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Pharmacokinetics, Safety, and Tolerability of SYN-020
Details : Undisclosed
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
March 25, 2021
Lead Product(s) : SYN-020
Therapeutic Area : Gastroenterology
Highest Development Status : Phase I
Recipient : Theriva Biologics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Bemotrizinol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Royal DSM
Deal Size : Inapplicable
Deal Type : Inapplicable
Bemotrizinol UV Filter Part 1 Clinical PK Evaluation in Topical MUsT Study
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 21, 2020
Lead Product(s) : Bemotrizinol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Royal DSM
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Study Phase : Phase II
Recipient : Raziel Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 31, 2017
Lead Product(s) : RZL-012
Therapeutic Area : Nutrition and Weight Loss
Highest Development Status : Phase II
Recipient : Raziel Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : NYX-2925
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Aptinyx
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Tolerability, PK of Oral NYX-2925 in Healthy Volunteers
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 15, 2016
Lead Product(s) : NYX-2925
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Aptinyx
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Dermatology
Study Phase : Phase I
Recipient : Novan
Deal Size : Inapplicable
Deal Type : Inapplicable
A Thorough ECG Study in Subjects With Acne Vulgaris Treated With SB204
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 20, 2015
Lead Product(s) : Berdazimer Sodium
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Recipient : Novan
Deal Size : Inapplicable
Deal Type : Inapplicable